7V0.XETRA Novogenia AG
- Market cap
- EUR 78.0M
- P/E
- 130.0x
- P/B
- 0.78x
- ROE
- 0.5%
- Dividend yield
- 4.59%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 7V0.XETRA undervalued?
Graham number7V0.XETRA trades 112.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Novogenia AG fundamental analysis
No fundamental analysis for Novogenia AG yet.
Novogenia AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Novogenia AG
Novogenia AG manufactures and sells personalized health products in global markets. The company offers products, such as personalized supplements and cosmetics; and services, including genetic testing, advanced therapies like personalized infusion therapies and reproductive genetics, and contract manufacturing. The company was formerly known as Darwin AG and changed its name to Novogenia AG in June 2026. The company was incorporated in 2021 and is based in Munich, Germany.
Full company profileNovogenia AG financial statements
Novogenia AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 111M | 210M | 18.2M | 25.3M | 54.3M |
| Gross Profit | 55.6M | 120M | 6.03M | 12.4M | 18.4M |
| Operating Income | 29.7M | 65.1M | -3.74M | 26.4M | -10.8M |
| EBITDA | - | 67.5M | 8.65M | 36.8M | 6.49M |
| Net Income | 19.4M | 45.1M | 39.7K | 18.5M | 545K |
| EPS | 6.46 | 3.76 | 0.00 | 6.15 | 0.05 |
| Balance Sheet | |||||
| Total Assets | 162M | 224M | 179M | 153M | 119M |
| Total Liabilities | 92.7M | 110M | 85.1M | 46.8M | 19.3M |
| Shareholders' Equity | 68.7M | 112M | 93.9M | 106M | 100M |
| Cash & Short-term Investments | 39.9M | 90.1M | 18.4M | 20.7M | 12.5M |
| Cash Flow | |||||
| Operating Cash Flow | 10.4M | 95.1M | -18.9M | -24.9M | -13.0M |
| Capital Expenditure | 891K | 2.61M | 1.45M | 4.34M | 8.67M |
| Free Cash Flow | 9.49M | 92.5M | -20.4M | -29.2M | -21.6M |
| Ratios | |||||
| ROE | 28.2% | 40.2% | 0.0% | 17.4% | 0.5% |
| ROA | 12.0% | 20.1% | 0.0% | 12.1% | 0.5% |
| Net Profit Margin | 17.4% | 21.4% | 0.2% | 73.0% | 1.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Novogenia AG dividends
- Dividend yield
- 4.59%
- Forward dividend
- 0.56 EUR
- Payout ratio
- 656.2%
- Ex-dividend date
- Jun 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 3.58M | 0.30 | 656.2% |
| 2024 | EUR 2.06M | 0.69 | 11.2% |
| 2023 | EUR 2.54M | 0.21 | 6,387.6% |
| 2022 | EUR 1.56M | 0.13 | 3.5% |
| 2021 | EUR 2.20M | 0.73 | 11.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 4:1 on Sep 18, 2025.
Who owns Novogenia AG
- Insiders 57.50%
- Institutions 0.10%
- Public & others 42.40%
- Shares outstanding 12.0M
- Free float 5.10M
Novogenia AG company profile
- Company name
- Novogenia AG
- Ticker
- 7V0.XETRA
- ISIN
- DE000A3C35W0
- Exchange
- XETRA Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 204
- Fiscal year end
- December
- Address
- Brienner Strasse 7, Munich, Germany, 80333
- Phone
- 49 20 500 450
- Website
- novogenia.com
About Novogenia AG
Novogenia AG manufactures and sells personalized health products in global markets. The company offers products, such as personalized supplements and cosmetics; and services, including genetic testing, advanced therapies like personalized infusion therapies and reproductive genetics, and contract manufacturing. The company was formerly known as Darwin AG and changed its name to Novogenia AG in June 2026. The company was incorporated in 2021 and is based in Munich, Germany.
Novogenia AG management
2- Dr. Daniel Wallerstorfer B.Sc., Ph.D.Founder, CEO & Member of Management Board
- Ms. Felix BauschMember of Management Board & C.I.O